1. Medtech Insight
  2. >>Business

Jury Backs C.R. Bard In AngioDynamics Antitrust Case

 
• By Elizabeth Orr

A New York jury found for C.R. Bard in an antitrust case brought by competitor AngioDynamics, who said that the way Bard packaged its catheter tip location systems preloaded into central lines was anti-competitive.

Gavel, scales, law books (Corgarashu/Alamy Stock Photo)
(Corgarashu / Alamy Stock Photo/Alamy Stock Photo)

Becton, Dickinson and Company subsidiary C.R. Bard’s approach to marketing its central catheter systems does not violate antitrust law, a New York federal jury concluded earlier this month in a case brought by competitor AngioDynamics, Inc..

The jury in the US District Court for the Northern District of New York found that AngioDynamics had failed to prove that Bard’s conduct qualified as “an unlawful tying arrangement,”...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.